Facebook
Twitter
LinkedIn
ForwardRecorded Presentations from the NCCN 2022 Annual Congress: Hematologic Malignancies™
The treatment of hematologic malignancies has become increasingly complex as a result of the rapid pace and number of advances in the biology and treatment of hematologic malignancies and the numerous drugs that have been approved or are in development, many with novel mechanisms of action.
Clinicians who manage patients with hematologic malignances are challenged to stay abreast of advances in the evolving diagnostic and treatment landscape to ensure optimal patient outcomes.
The NCCN 2022 Annual Congress: Hematologic Malignancies™ will focus on updates to the NCCN Guidelines®, new, emerging and novel therapeutic agents, advances in cancer care, and the practical management of patients with hematologic malignancies, as well as re-vaccination of patients with hematologic malignancies and hematopoietic growth factors.
Target Audience
This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, PAs, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
The ultimate goal for NCCN continuing education is to change patient outcomes by improving the competence and performance of clinicians.
The goal of the NCCN 2022 Annual Congress: Hematologic Malignancies™ is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, PAs, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and key updates in the NCCN Guidelines® to optimize the management of patients with various hematologic malignancies.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty & NCCN Staff Disclosures
Click here to download the faculty disclosures for this program.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing